Literature DB >> 25806224

Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).

Teresa Morán1, Vanesa Quiroga1, María de Los Llanos Gil1, Laia Vilà1, Nuria Pardo1, Enric Carcereny1, Laia Capdevila1, Ana M Muñoz-Mármol1, Rafael Rosell1.   

Abstract

Entities:  

Year:  2013        PMID： 25806224      PMCID： PMC4369851          DOI： 10.3978/j.issn.2218-6751.2013.03.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  56 in total

1.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

2.  Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

Authors:  J Carlijn van Gaal; Uta E Flucke; Melissa H S Roeffen; Eveline S J M de Bont; Stefan Sleijfer; Annelies M C Mavinkurve-Groothuis; Albert J H Suurmeijer; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

3.  Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Authors:  Marta Salido; Lara Pijuan; Luz Martínez-Avilés; Ana B Galván; Israel Cañadas; Ana Rovira; Montserrat Zanui; Alejandro Martínez; Raquel Longarón; Francisco Sole; Sergio Serrano; Beatriz Bellosillo; Murry W Wynes; Joan Albanell; Fred R Hirsch; Edurne Arriola
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

Review 4.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authors:  Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

5.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

6.  Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Authors:  D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

7.  EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Kimie Nomura; Hironori Ninomiya; Michiyo Okui; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Toshiro Niki; Hiroyuki Mano; Yuichi Ishikawa
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

8.  Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.

Authors:  Larisa V Debelenko; Diane C Arthur; Svetlana D Pack; Lee J Helman; David S Schrump; Maria Tsokos
Journal:  Lab Invest       Date:  2003-09       Impact factor: 5.662

9.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582
View more
  4 in total

Review 1.  Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.

Authors:  Shanthi Kanthala; Sandeep Pallerla; Seetharama Jois
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

2.  First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Authors:  Tianhong Li; Patricia LoRusso; Michael L Maitland; Sai-Hong Ignatius Ou; Erkut Bahceci; Howard A Ball; Jung Wook Park; Geoffrey Yuen; Anthony Tolcher
Journal:  J Hematol Oncol       Date:  2016-03-10       Impact factor: 17.388

3.  Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.

Authors:  Se Jin Oh; Kyung Hee Noh; Young-Ho Lee; Soon-Oh Hong; Kwon-Ho Song; Hyo-Jung Lee; Soyeon Kim; Tae Min Kim; Ju-Hong Jeon; Jae Hong Seo; Dong-Wan Kim; Tae Woo Kim
Journal:  Oncotarget       Date:  2015-11-24

Review 4.  New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer.

Authors:  Amy M Weise; Shirish Gadgeel
Journal:  Lung Cancer (Auckl)       Date:  2014-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.